JP2014058562A5 - - Google Patents

Download PDF

Info

Publication number
JP2014058562A5
JP2014058562A5 JP2013259956A JP2013259956A JP2014058562A5 JP 2014058562 A5 JP2014058562 A5 JP 2014058562A5 JP 2013259956 A JP2013259956 A JP 2013259956A JP 2013259956 A JP2013259956 A JP 2013259956A JP 2014058562 A5 JP2014058562 A5 JP 2014058562A5
Authority
JP
Japan
Prior art keywords
solution
composition
hydrophobic
chain
protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013259956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014058562A (ja
JP5878912B2 (ja
Filing date
Publication date
Priority claimed from US11/971,482 external-priority patent/US20090176892A1/en
Application filed filed Critical
Publication of JP2014058562A publication Critical patent/JP2014058562A/ja
Publication of JP2014058562A5 publication Critical patent/JP2014058562A5/ja
Application granted granted Critical
Publication of JP5878912B2 publication Critical patent/JP5878912B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013259956A 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 Active JP5878912B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/971,482 US20090176892A1 (en) 2008-01-09 2008-01-09 Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US11/971,482 2008-01-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010542394A Division JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014110975A Division JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Publications (3)

Publication Number Publication Date
JP2014058562A JP2014058562A (ja) 2014-04-03
JP2014058562A5 true JP2014058562A5 (enExample) 2014-07-17
JP5878912B2 JP5878912B2 (ja) 2016-03-08

Family

ID=40845092

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010542394A Withdrawn JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2013259956A Active JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010542394A Withdrawn JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Country Status (4)

Country Link
US (3) US20090176892A1 (enExample)
EP (1) EP2240165B1 (enExample)
JP (5) JP2011509311A (enExample)
WO (1) WO2009089506A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2633070C (en) 2005-12-19 2016-03-08 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
JP5281358B2 (ja) * 2008-10-27 2013-09-04 学校法人常翔学園 高分子、経上皮吸収促進剤、及び医薬用製剤
JP5820378B2 (ja) 2009-09-09 2015-11-24 ファーマイン コーポレーションＰｈａｒｍａｉｎ Ｃｏｒｐｏｒａｔｉｏｎ 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
US20120094924A1 (en) * 2010-10-14 2012-04-19 Nitto Denko Corporation Nucleic acid delivery compounds
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
AU2015343207B2 (en) * 2014-11-03 2019-10-31 Pharmain Corporation Method of production of graft co-polymer excipient with a superior peptide and protein binding property
WO2018017954A1 (en) * 2016-07-21 2018-01-25 Rutgers, The State University Of New Jersey Antimicrobial cationic systems and methods of use
US20190275108A1 (en) * 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
FR3083086A1 (fr) * 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
BR112020011479A2 (pt) 2017-12-07 2020-11-17 Adocia composições na forma de uma solução aquosa injetável caracterizada pelo fato de que compreende amilina, um agonista do receptor de amilina ou um análogo de amilina e um co-poliaminoácido

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5116603A (en) 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
CA2133323C (en) * 1992-04-03 2010-10-26 Francis C. Szoka, Jr. Self-assembling polynucleotide delivery system
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
ES2199226T3 (es) * 1992-09-04 2004-02-16 The General Hospital Corporation Polimeros biocompatibles que contienen mitades diagnosticas o terapeuticas.
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
IL112920A (en) * 1994-03-07 2003-04-10 Dow Chemical Co Composition comprising a dendritic polymer complexed with at least one unit of biological response modifier and a process for the preparation thereof
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
CA2224253A1 (en) * 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
EP0856026A1 (en) * 1995-10-19 1998-08-05 Receptagen Corporation Discrete-length polyethylene glycols
JP3737518B2 (ja) 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
CN1271277A (zh) * 1997-07-18 2000-10-25 因菲米德有限公司 用于生物活性物质控释的生物可降解的大分子的单体
US6468532B1 (en) * 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
ATE445006T1 (de) * 1998-08-10 2009-10-15 Us Gov Health & Human Serv Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
JP4740455B2 (ja) * 1998-08-12 2011-08-03 イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 硫酸アンモニウム勾配を使用して調製されるリポソーム性ブピバカイン組成物
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
AU3581300A (en) * 1999-01-08 2000-07-24 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
CN1419504A (zh) * 2000-02-22 2003-05-21 大赛璐化学工业株式会社 气囊用气体发生器、偏流部件、冷却/过滤装置支撑部件、冷却器及壳体
CN1487836A (zh) * 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
CN1462191B (zh) * 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
CA2797652C (en) * 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
US20040092432A1 (en) * 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
EP1330261B1 (en) * 2000-10-20 2010-06-09 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
WO2002048192A2 (en) * 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
JP2004521093A (ja) * 2000-12-13 2004-07-15 イーライ・リリー・アンド・カンパニー グルカゴン様インスリン刺激性ペプチドを用いる長期治療計画
JP4775985B2 (ja) * 2000-12-27 2011-09-21 三井化学株式会社 重合体及びその製造方法
ES2315350T3 (es) * 2001-01-12 2009-04-01 Waratah Pharmaceuticals Inc. Composiciones para la introduccion de la neogenesis de islotes, que contienen unos ligandos para el receptor de gastrina/cck y ligandos para el receptor de efg.
AU2002308706A1 (en) * 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
AU2002316811A1 (en) * 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
US6586524B2 (en) * 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
MXPA04001525A (es) * 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
WO2003028626A2 (en) * 2001-10-01 2003-04-10 Eli Lilly And Company Glucagon-like peptides (glp-1) and treatment of respiratory distress
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
JP4124734B2 (ja) * 2001-11-26 2008-07-23 アスビオファーマ株式会社 経鼻吸収用医薬組成物
EP2409569B1 (en) * 2002-02-20 2017-08-16 Emisphere Technologies, Inc. Method for administering GLP-1 molecules
US7138105B2 (en) * 2002-02-27 2006-11-21 Pharmain Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US6705987B2 (en) * 2002-04-17 2004-03-16 Endocare, Inc. Penile seal and constriction ring
EP2028192A1 (en) * 2002-07-04 2009-02-25 Zealand Pharma A/S GLP-1 and methods for treating diabetes
WO2004014451A1 (en) 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
EP1539210A4 (en) 2002-09-06 2006-06-07 Bayer Pharmaceuticals Corp GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
GB0221941D0 (en) 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
ATE404175T1 (de) * 2003-03-31 2008-08-15 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
EP1631308B1 (en) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
ATE529126T1 (de) * 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
AR047776A1 (es) * 2003-12-16 2006-02-22 Sod Conseils Rech Applic Composiciones farmaceuticas glp - 1
US8372966B2 (en) 2003-12-19 2013-02-12 University Of Cincinnati Oligonucleotide decoys and methods of use
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
WO2005120546A2 (en) * 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
FR2867679B1 (fr) * 2004-03-17 2008-08-22 Oreal Composition cosmetiques comprenant des polyamines modifiees et utilisations desdites compositions.
US7985424B2 (en) * 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
NZ550604A (en) * 2004-04-20 2010-09-30 Dendritic Nanotechnologies Inc Dendritic polymers with enhanced amplification and interior functionality
US20060134166A1 (en) * 2004-05-25 2006-06-22 Luthra Ajay K Absorbable biocompatible materials
AU2005326322B2 (en) * 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
WO2006014425A1 (en) * 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
KR101276754B1 (ko) * 2004-07-19 2013-06-19 바이오콘 리미티드 인슐린―올리고머 접합체，제형 및 이들의 용도
KR100675834B1 (ko) * 2004-10-28 2007-01-29 한국전자통신연구원 루프백 형 파장분할다중방식의 수동형 광 네트워크
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US20100041612A1 (en) 2005-09-08 2010-02-18 Martin Beinborn Fragments of the Glucagon-Like Peptide-1 and Uses Thereof
PL1931397T3 (pl) * 2005-10-05 2009-08-31 Essity Hygiene & Health Ab Wyrób absorpcyjny zawierający obszary hydrofilowe i hydrofobowe
US8258259B2 (en) 2005-10-25 2012-09-04 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
PT1965823T (pt) 2005-11-04 2016-08-18 Glaxosmithkline Llc Métodos para administração de agentes hipoglicémicos
CA2633070C (en) * 2005-12-19 2016-03-08 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
ES2937113T3 (es) 2006-01-20 2023-03-24 Starpharma Pty Ltd Macromolécula modificada
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same

Similar Documents

Publication Publication Date Title
JP2014058562A5 (enExample)
JP2011509311A5 (enExample)
Ding et al. Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications
Ryu et al. Chitosan oral patches inspired by mussel adhesion
Li et al. Biodegradable and injectable hydrogels in biomedical applications
Hong et al. Dynamic bonds between boronic acid and alginate: hydrogels with stretchable, self-healing, stimuli-responsive, remoldable, and adhesive properties
Kumar et al. Why Chitosan? From properties to perspective of mucosal drug delivery
Chen et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules
Hutanu et al. Recent applications of polyethylene glycols (PEGs) and PEG derivatives
US9265723B2 (en) Long acting insulin composition
Werle et al. Modified chitosans for oral drug delivery
ES2733734T3 (es) Profármacos que comprenden un conjugado exendina enlazador
Sonker et al. Review of recent advances and their improvement in the effectiveness of hydrogel-based targeted drug delivery: A hope for treating cancer
ES2679195T3 (es) Método para la preparación de un sistema de liberación controlada
JP2023504853A (ja) 炎症応答性を有する抗炎症性ハイドロゲル
Schulz et al. Improving oral drug bioavailability with polycations?
JP2014514275A5 (enExample)
JP2012532185A5 (enExample)
JP2013536198A (ja) 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法
Cui et al. Preparation and evaluation of chitosan‐ethylenediaminetetraacetic acid hydrogel films for the mucoadhesive transbuccal delivery of insulin
CN1556712A (zh) 含dds化合物的药用组合物
Berezin et al. Chitosan conjugates with biologically active compounds: Design strategies, properties, and targeted drug delivery
BRPI0714718B1 (pt) Composição de micela polimérica de encapsulamento de polipeptídeos ou proteínas e seu método de preparo
Lee et al. Targeted cellular delivery of robust enzyme nanoparticles for the treatment of drug-induced hepatotoxicity and liver injury
JP2019511497A5 (enExample)